经口机器人手术与口咽癌手术短期和长期结局及费用的关联
基于2010至2012年MarketScan数据库3573例接受口咽癌手术切除患者的回顾性横断面分析,经口机器人手术(TORS)使用率从2010年4.1%升至2012年13.2%。TORS与较低的辅助放化疗使用、治疗后胃造瘘和气管造瘘依赖及较低的总体治疗相关费用相关。
要点
- TORS使用率从2010年4.1%上升至2012年13.2%。
- TORS组治疗期间气管造瘘率3.9% vs 非TORS组11.4%。
- TORS组治疗后胃造瘘管使用率21.9% vs 非TORS组34.2%。
核心结论
- TORS用于口咽癌手术切除在美国呈增长趋势,与显著较低的辅助放化疗使用、晚期胃造瘘和气管造瘘依赖及较低的总体治疗相关费用相关。
研究设计与样本
- 回顾性横断面分析,纳入2010至2012年MarketScan Commercial Claim and Encounters数据库中3573例接受口咽癌根治性手术的患者。
主要发现
- TORS手术304例(8.5%);94.7%患者年龄40至64岁,70.7%为男性。
- TORS使用率从2010年手术病例的4.1%升至2012年的13.2%。
- TORS组治疗期间气管造瘘率3.9% vs 非TORS组11.4%,治疗后胃造瘘管使用率21.9% vs 非TORS组34.2%。
- 多因素分析中,TORS与术后并发症或住院时间无显著差异。
- 接受放疗的患者中,TORS后接受放化疗的可能性显著更低(OR 0.52,95%CI 0.29-0.90);1年时TORS与治疗后胃造瘘(OR 0.54,95%CI 0.30-0.95)和治疗期间气管造瘘(OR 0.17,95%CI 0.06-0.55)的 odds 显著降低相关,并与总体治疗相关费用显著降低相关(平均增量费用 -22724美元)。
关键数值与推荐
- TORS组治疗期间气管造瘘率3.9% vs 非TORS组11.4%。
- TORS组治疗后胃造瘘管使用率21.9% vs 非TORS组34.2%。
- 接受放疗者中TORS后放化疗OR 0.52(95%CI 0.29-0.90)。
- 1年时TORS与治疗后胃造瘘OR 0.54(95%CI 0.30-0.95)相关。
- 1年时TORS与治疗期间气管造瘘OR 0.17(95%CI 0.06-0.55)相关,平均增量费用 -22724美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The treatment of oropharyngeal cancer has undergone a paradigm shift in the past 2 decades, with an increase in the use of nonoperative treatment owing to poor functional outcomes associated with traditional surgical approaches. Transoral robotic surgery (TORS) allows surgical resection of oropharyngeal cancer (OPC) with less morbidity through a minimally invasive approach. OBJECTIVE: To investigate the relationship among TORS and short- and long-term outcomes and costs in surgically treated patients with OPC. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cross-sectional analysis of 3573 patients who underwent an ablative procedure for OPC in 2010 to 2012 using the MarketScan Commercial Claim and Encounters database. MAIN OUTCOMES AND MEASURES: The association between TORS and short- and long-term outcomes, length of hospitalization, and treatment-related costs was analyzed using descriptive statistics and multivariate regression modeling. RESULTS: Transoral robotic surgery was performed in 304 surgical cases (8.5%); 94.7% of patients were 40 to 64 years old, and 70.7% were male. The use of TORS increased from 4.1% of surgical cases in 2010 to 13.2% of surgical cases in 2012. Patients who underwent TORS had a lower rate of tracheotomy during treatment (3.9% vs 11.4%), and posttreatment gastrostomy tube use (21.9% vs 34.2%), compared with patients undergoing non-TORS procedures. On multivariate analysis, TORS was not associated with significant differences in postoperative complications or length of hospitalization. There was no significant difference in the odds of receiving postoperative radiation therapy between patients who underwent TORS and those who did not; however, among patients receiving radiation therapy, chemoradiation was significantly less likely following TORS (odds ratio [OR], 0.52; 95% CI, 0.29-0.90). TORS was associated with significantly decreased odds of posttreatment gastrostomy (OR, 0.54; 95% CI. 0.30-0.95) and tracheostomy during treatment (OR, 0.17; 95% CI, 0.06-0.55) at 1 year, and was associated with significantly decreased overall treatment-related costs of care (mean incremental cost, -$22 724). CONCLUSIONS AND RELEVANCE: The use of TORS for surgical resection of OPC is increasing in the United States and is associated with significantly lower use of adjuvant chemoradiation, late gastrostomy and tracheostomy dependence, and lower overall treatment-related costs of care. These data have implications for discussions of value in OPC care at a time of health care reform.
引用
- Motz K, Chang HY, Quon H, et al. Association of Transoral Robotic Surgery With Short-term and Long-term Outcomes and Costs of Care in Oropharyngeal Cancer Surgery. JAMA Otolaryngol Head Neck Surg. 2017. PMID: 28358930. doi:10.1001/jamaoto.2016.4634
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。